Acceder

José Bartolo Nieto Campuzano

Buscador

Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008 Feb 1;26(4):577-84. Epub 2007 Dec 17. PubMed PMID: 18086801.
AÑO: 2008; IF: 17.157
Bastos Oreiro M, Castilla-Llorente C, de la Guía AL, de Paz R, Van Domselaar M, Nieto J, Rodriguez A, Gallardo D, Canales M; GETH (Grupo Español de Trasplantes Hematopoyéticos y Terapia Celular). Fecal calprotectin in allogeneic stem cell transplantation for the diagnosis of acute intestinal graft versus host disease. Bone Marrow Transplant. 2012 Sep;47(9):1241-2. doi: 10.1038/bmt.2011.241. Epub 2012 Feb 6. PubMed PMID: 22307017.
AÑO: 2012; IF: 3.541
Martín-Antonio B, Suarez-Lledo M, Arroyes M, Fernández-Avilés F, Martínez C, Rovira M, Espigado I, Gallardo D, Bosch A, Buño I, Martínez-Laperche C, Jiménez-Velasco A, de la Cámara R, Brunet S, Nieto JB, Urbano-Ispizua A. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT. Bone Marrow Transplant. 2013 Sep;48(9):1205-11. doi: 10.1038/bmt.2013.43. PubMed PMID: 23542224.
AÑO: 2013; IF: 3.466
Muñoz-Ballester J, Chen-Liang TH, Hurtado AM, Heras I, de Arriba F, García-Malo MD, Iniesta P, Lozano ML, Nieto JB, Ortuño FJ, Osma Mdel M, Padilla J, Teruel-Montoya R, Vicente V, Castilla-Llorente C, Jerez A. Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations. Br J Haematol. 2016 Mar;172(6):937-46. doi: 10.1111/bjh.13917. Epub 2016 Jan 5. PubMed PMID: 26728704.
AÑO: 2016; IF: 5.67
Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín-Antonio B, Guillem V, Bosch-Vizcaya A, Bento L, González-Rivera M, Balsalobre P, Kwon M, Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas-Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua A, Solano C, Gallardo D, Díez-Martín JL, Buño I; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH).. The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS One. 2015 Oct 16;10(10):e0140454. doi: 10.1371/journal.pone.0140454. PubMed PMID: 26473355; PubMed Central PMCID: PMC4608671.
AÑO: 2015; IF: 3.057

Instituto de Investigación Sanitaria Acreditado

ISCII